Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

Eli Lilly (NYSE:LLY) has launched its popular weight loss/diabetes therapy Mounjaro in India, beating its biggest rival, Novo ...

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Workouts at gyms to combat muscle loss caused by GLP-1 drugs are gaining traction, but do they differ from regular strength ...

Experts explain if Ozempic causes hair loss, and how the medication may indirectly lead to weight loss-related hair loss due ...

AFTER months of careful research, Jennifer Dootson started weight loss injections, hoping to end two decades of yo-yo dieting ...

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country’s ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

"It's called GLP-1 receptor," said Dr. Atul Malhotra from the UC San Diego School of Medicine. It’s already FDA-approved to ...